CAR T cell therapy shows promising Phase II trial results in multiple myeloma

The chimeric antigen receptor (CAR) T cell therapy anitocabtagene autoleucel (anito-cel) continued to show strong results in treating relapsed/refractory multiple myeloma, according to new trial data from researchers at The University of Texas MD…

Continue Reading

News Source: medicalxpress.com